1st Quarter - Report
LEAVITT PARTNERS, LLC for SAVE RARE TREATMENTS TASK FORCE
Income
$40,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT CLAYTON ALSPACH | Chief Health Counsel for Chairman - House E&C Committee (E&C);Counsel - E&C, Clerk - E&C, and Paid Intern - E&C |
| SHANNON ROHN DEERE | — |
| JOSH TRENT | Chief Health Counsel for Chairman - House E&C Committee (E&C); Deputy Chief Health Counsel - E&C; Professional Staff - E&C; Health Care Policy Advisor - Senate; Deputy Director Office of Refugee Resettlement HHS; WH Office of Presidential Personnel |
Affiliated organisations
| Organisation | Location |
|---|---|
| AGIOS PHARMACEUTICALS | Cambridge, MA, US |
| ALKERMES, INC. | Waltham, MA, US |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.